Great businesses do not grow in straight lines. They compound over decades through a combination of product leadership, pricing power, operational excellence, and relentless reinvestment in innovation. Novo Nordisk (NYSE: NVO), arguably the world’s most dominant metabolic-care company, has spent three decades building precisely such a machine. Its FY25 results reaffirm that the engine remains intact. Yet the market’s sharp reaction to management’s cautious 2026 guidance reminds us of an uncomfortable truth: even the highest-quality franchises periodically encounter phases where expectations run ahead of reality.

For long-term investors, the task is not to react to quarterly volatility, but to ask a more fundamental question: has the underlying compounding capability of Novo Nordisk been structurally impaired, or is this merely a cyclical pause within a much larger secular growth story?

A Franchise Built on Relentless Focus

Novo Nordisk’s strategic clarity is striking. Unlike diversified pharma conglomerates that spread capital across multiple therapeutic areas, Novo has spent decades concentrating on diabetes, obesity, and rare endocrine disorders. This focus has enabled deep scientific expertise, manufacturing scale, regulatory credibility, and physician trust—advantages that are difficult to replicate.

In FY25, the company delivered net sales of DKK 309 billion, growing 10% at constant exchange rates. More importantly, this growth was powered by categories with long runways rather than transient opportunities. Obesity care grew over 30% at constant currency, while GLP-1–based diabetes therapies continued to expand despite pressure on older insulin franchises. These numbers matter because they reflect structural demand rather than cyclical tailwinds.

Obesity is not a fashion. It is a chronic disease with rising prevalence across both developed and emerging markets. Novo Nordisk’s ability to define treatment paradigms in this category mirrors what it achieved in insulin three decades ago. That historical precedent is crucial: once Novo becomes embedded in clinical guidelines and reimbursement systems, displacement becomes extraordinarily difficult.

Wegovy and Ozempic: More Than Blockbusters

Wegovy and Ozempic are often described as blockbuster drugs. That label understates their strategic significance. These products represent platforms around which entire ecosystems of follow-on therapies, delivery mechanisms, and combinations can be built.

In FY25, Wegovy grew more than 40% at constant currency, while Ozempic grew around 10%. These are exceptional numbers for products that already generate tens of billions in revenue. But the deeper insight is that Novo continues to broaden the addressable market through new formulations, dosage strengths, and delivery routes—including the world’s first oral GLP-1 obesity pill.

This matters because platform drugs extend economic life far beyond the nominal patent expiry of a single molecule. Even as semaglutide patents begin to expire in selected geographies, Novo’s next-generation combinations such as CagriSema and other pipeline assets provide a bridge to the next growth cycle.

Operating Discipline in a Capital-Intensive Phase

Operating profit in FY25 grew 6% at constant currency despite roughly DKK 8 billion in transformation and capacity-expansion costs. Strip out these one-offs and underlying profit growth exceeds 13%. This tells us two things.

First, Novo still enjoys meaningful pricing power, even in an environment of increasing payer scrutiny. Second, management is willing to sacrifice short-term margins to protect long-term capacity and competitive positioning. That is a hallmark of a compounding organisation.

Capital expenditure of around DKK 55 billion in 2026 may appear aggressive, but this is exactly what one would expect from a business facing demand that exceeds current manufacturing capacity. In high-quality franchises, reinvestment at scale is not a red flag—it is a prerequisite for sustaining growth.

Why the Market Panicked

The company’s 2026 guidance of negative 5% to negative 13% adjusted sales growth at constant currency triggered a violent market reaction. The reasons are understandable: pricing compression in the US, “Most Favoured Nations” policies, patent expirations in some markets, and intensifying competition from peers such as Eli Lilly.

However, investors should separate two different phenomena: near-term earnings volatility and long-term franchise erosion. Guidance reflects a reset in pricing and accounting dynamics, not a collapse in patient demand. In fact, Novo expects free cash flow to rise to DKK 35–45 billion in 2026, despite the headline decline in adjusted earnings.

Moreover, part of the reported volatility is driven by one-off items such as the USD 4.2 billion reversal related to US rebate provisions. These distort comparability but do not alter the economics of the underlying business.

Competition Is Rising—But So Are Barriers

Yes, the GLP-1 market is becoming crowded. But competition does not automatically destroy value. In large, rapidly expanding markets, multiple winners can coexist, especially when switching costs are high and clinical differentiation matters.

Novo’s advantages lie in manufacturing scale, supply-chain reliability, long-standing physician relationships, and deep regulatory expertise. These are not easily replicated by late entrants. Furthermore, Novo’s early investment in combination therapies and oral formulations creates optionality that many competitors lack.

History offers a useful parallel. Insulin markets have been competitive for decades, yet Novo remains the global leader with attractive economics. There is little reason to assume that GLP-1 therapies will follow a radically different path.

Balance Sheet Strength and Shareholder Alignment

Novo Nordisk continues to return significant capital to shareholders while funding aggressive reinvestment. In FY25, it returned DKK 52 billion via dividends and announced a new DKK 15 billion buyback programme.

This balance—between reinvestment and shareholder returns—is a defining feature of high-quality compounders. It signals confidence in the business’s ability to generate surplus cash over long periods.

Technical Weakness Is Not Business Weakness

From a market perspective, the stock is deeply oversold, with RSI near 22 and price well below key moving averages. Such conditions often reflect emotional capitulation rather than fundamental deterioration.

Long-term investors should treat this not as a signal of permanent impairment, but as evidence of short-term uncertainty being aggressively discounted.

The Bigger Picture

Novo Nordisk is attempting something extraordinarily difficult: scaling one of the largest pharmaceutical franchises in history while simultaneously reinventing it. Periods of turbulence are inevitable.

The core ingredients of compounding remain firmly in place:

  • Structural demand for metabolic therapies
  • Platform products with long life cycles
  • Strong balance sheet and cash generation
  • Relentless reinvestment in innovation

If these remain intact—and current evidence suggests they do—then FY26 will likely be remembered not as the start of decline, but as a transitional year.

For investors who think in decades rather than quarters, the question is not whether Novo will face competition or pricing pressure. It always has. The real question is whether Novo retains the organisational capability to adapt, innovate, and compound. On that front, its track record remains one of the best in global pharmaceuticals.

In investing, the greatest opportunities often emerge when high-quality businesses face temporary discomfort. Novo Nordisk today looks less like a broken franchise and more like a great compounding machine going through a necessary reset.